

BIOMARIN PHARMACEUTICAL INC  
Form 4  
October 31, 2016

**FORM 4**

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549**

OMB APPROVAL

OMB Number: 3235-0287  
Expires: January 31, 2015  
Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person \*  
**BIENAIME JEAN JACQUES**

2. Issuer Name and Ticker or Trading Symbol  
**BIOMARIN PHARMACEUTICAL INC [BMRN]**

5. Relationship of Reporting Person(s) to Issuer  
  
(Check all applicable)  
 Director  10% Owner  
 Officer (give title below)  Other (specify below)  
Chief Executive Officer

(Last) (First) (Middle)  
**C/O BIOMARIN PHARMACEUTICAL INC., 770 LINDARO ST.**  
  
(Street)

3. Date of Earliest Transaction (Month/Day/Year)  
**10/27/2016**

**SAN RAFAEL, CA 94901**  
  
(City) (State) (Zip)

4. If Amendment, Date Original Filed(Month/Day/Year)

6. Individual or Joint/Group Filing(Check Applicable Line)  
 Form filed by One Reporting Person  
 Form filed by More than One Reporting Person

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

| 1. Title of Security (Instr. 3) | 2. Transaction Date (Month/Day/Year) | 2A. Deemed Execution Date, if any (Month/Day/Year) | 3. Transaction Code |   | 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) |            | 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) | 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 7. Nature of Ownership (Instr. 4) |       |
|---------------------------------|--------------------------------------|--|---------------------|---|---|------------|---|--|-----------------------------------|-------|
|                                 |                                      |  | Code                | V | Amount  | (A) or (D) |   |  |                                   | Price |
| Common Stock                    | 10/27/2016 <sup>(1)</sup>            | 10/27/2016   | M                   |   | 60,000  | A          | \$ 14.39  | 383,368  | D                                 |       |
| Common Stock                    | 10/27/2016 <sup>(1)</sup>            | 10/27/2016   | S                   |   | 60,000  | D          | \$ 81.3408  | 323,368  | D                                 |       |
| Common Stock                    | 10/28/2016 <sup>(1)</sup>            | 10/28/2016   | M                   |   | 60,000  | A          | \$ 14.39  | 383,368  | D                                 |       |
| Common Stock                    | 10/28/2016 <sup>(1)</sup>            | 10/28/2016   | S                   |   | 60,000  | D          | \$ 81.2665  | 323,368  | D                                 |       |

(3)

|                 |        |   |  |
|-----------------|--------|---|--|
| Common<br>Stock | 25,758 | I | Shares<br>held by<br>Bienaime<br>Family<br>Trust |
|-----------------|--------|---|--|

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.**

SEC 1474  
(9-02)

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned**  
(e.g., puts, calls, warrants, options, convertible securities)

| 1. Title of<br>Derivative<br>Security<br>(Instr. 3)     | 2. Conversion<br>or Exercise<br>Price of<br>Derivative<br>Security | 3. Transaction Date<br>(Month/Day/Year) | 3A. Deemed<br>Execution Date, if<br>any<br>(Month/Day/Year) | 4.<br>Transaction<br>Code<br>(Instr. 8) | 5. Number of<br>Derivative<br>Securities<br>Acquired (A)<br>or Disposed of<br>(D)<br>(Instr. 3, 4,<br>and 5) | 6. Date Exercisable and<br>Expiration Date<br>(Month/Day/Year) | 7. Title and Amount of<br>Underlying Securities<br>(Instr. 3 and 4) | Amount<br>or<br>Number<br>of Shares |  |
|---|--|---|---|---|--|--|---|-------------------------------------|--|
|   |  |   |   | Code                                    | V (A) (D)  | Date<br>Exercisable  | Expiration<br>Date  | Title                               |  |
| Stock<br>Option<br>(right to<br>buy<br>Common<br>Stock) | \$ 14.39   | 10/27/2016 <sup>(1)</sup>               | 10/27/2016  | M                                       | 60,000   | 11/12/2009 05/11/2019  | Common<br>Stock   | 60,000                              |  |
| Stock<br>Option<br>(right to<br>buy<br>Common<br>Stock) | \$ 14.39   | 10/28/2016 <sup>(1)</sup>               | 10/28/2016  | M                                       | 60,000   | 11/12/2009 05/11/2019  | Common<br>Stock   | 60,000                              |  |

## Reporting Owners

| Reporting Owner Name / Address   | Relationships |           |                         |       |
|--|---------------|-----------|-------------------------|-------|
|  | Director      | 10% Owner | Officer                 | Other |
| BIENAIME JEAN JACQUES<br>C/O BIOMARIN PHARMACEUTICAL INC.<br>770 LINDARO ST. | X             |           | Chief Executive Officer |       |

SAN RAFAEL, CA 94901

## Signatures

/s/ Laura Randall Woodhead,  
Attorney-in-Fact

10/31/2016

\_\_Signature of Reporting Person

Date

## Explanation of Responses:

\* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Trade made pursuant to a 10b5-1 plan executed on June 9, 2016. Mr. Bienaime's former spouse will receive the net proceeds from the  
(1) shares sold in this transaction in connection with cash payments owed to her pursuant to a marital separation agreement between her and Mr. Bienaime.

The price in column 4 is the weighted average price. The price actually received ranged from \$80.36 to \$83.261. The reporting person  
(2) shall provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price.

The price in column 4 is the weighted average price. The price actually received ranged from \$79.20 to \$82.45. The reporting person shall  
(3) provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price.

(4) Reflects the number of stock options outstanding after the transaction from this specific stock option grant.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.